Barclays
ENTA icon

Barclays’s Enanta Pharmaceuticals ENTA Stock Holding History

Barclays’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Sell
18,394
-36,595
-67% -$491K ﹤0.01% 3600
2025
Q4 		$867K Buy
54,989
+13,368
+32% +$170K ﹤0.01% 3540
2025
Q3 		$498K Sell
41,621
-6,267
-13% -$50.1K ﹤0.01% 3812
2025
Q2 		$362K Buy
47,888
+12,503
+35% +$75.2K ﹤0.01% 3937
2025
Q1 		$195K Sell
35,385
-10,123
-22% -$62.5K ﹤0.01% 4057
2024
Q4 		$262K Buy
45,508
+18,070
+66% +$173K ﹤0.01% 4182
2024
Q3 		$284K Buy
27,438
+20,478
+294% +$268K ﹤0.01% 4118
2024
Q2 		$90.3K Sell
6,960
-7,160
-51% -$96.7K ﹤0.01% 3952
2024
Q1 		$247K Sell
14,120
-27,180
-66% -$360K ﹤0.01% 4004
2023
Q4 		$389K Buy
41,300
+24,081
+140% +$224K ﹤0.01% 4029
2023
Q3 		$192K Sell
17,219
-33,685
-66% -$543K ﹤0.01% 3318
2023
Q2 		$1.09M Buy
50,904
+24,654
+94% +$727K ﹤0.01% 2248
2023
Q1 		$1.06M Sell
26,250
-24,649
-48% -$1.18M ﹤0.01% 2687
2022
Q4 		$2.37M Buy
50,899
+5,531
+12% +$252K ﹤0.01% 2143
2022
Q3 		$2.35M Buy
45,368
+39,571
+683% +$2.31M ﹤0.01% 1637
2022
Q2 		$274K Sell
5,797
-9,173
-61% -$498K ﹤0.01% 3253
2022
Q1 		$1.07M Sell
14,970
-10,068
-40% -$655K ﹤0.01% 2344
2021
Q4 		$1.87M Buy
25,038
+2,281
+10% +$179K ﹤0.01% 2429
2021
Q3 		$1.29M Buy
22,757
+11,547
+103% +$571K ﹤0.01% 2627
2021
Q2 		$495K Sell
11,210
-12,327
-52% -$604K ﹤0.01% 3078
2021
Q1 		$1.16M Sell
23,537
-1,233
-5% -$61.5K ﹤0.01% 2683
2020
Q4 		$1.04M Sell
24,770
-1,461
-6% -$64.3K ﹤0.01% 2729
2020
Q3 		$1.2M Buy
26,231
+8,255
+46% +$400K ﹤0.01% 2526
2020
Q2 		$904K Buy
17,976
+3,211
+22% +$166K ﹤0.01% 2850
2020
Q1 		$759K Sell
14,765
-33,605
-69% -$1.79M ﹤0.01% 3234
2019
Q4 		$2.99M Buy
48,370
+12,115
+33% +$751K ﹤0.01% 2571
2019
Q3 		$2.18M Sell
36,255
-385
-1% -$28.6K ﹤0.01% 2758
2019
Q2 		$3.09M Sell
36,640
-19,584
-35% -$1.76M ﹤0.01% 2398
2019
Q1 		$5.37M Buy
56,224
+44,990
+400% +$4.04M ﹤0.01% 1611
2018
Q4 		$795K Sell
11,234
-17,299
-61% -$1.33M ﹤0.01% 3348
2018
Q3 		$2.44M Buy
28,533
+23,078
+423% +$2.31M ﹤0.01% 2645
2018
Q2 		$632K Sell
5,455
-2,642
-33% -$264K ﹤0.01% 3725
2018
Q1 		$654K Sell
8,097
-18,863
-70% -$1.45M ﹤0.01% 3680
2017
Q4 		$1.58M Buy
26,960
+325
+1% +$16.3K ﹤0.01% 2664
2017
Q3 		$1.25M Sell
26,635
-3,325
-11% -$134K ﹤0.01% 2800
2017
Q2 		$1.08M Sell
29,960
-29,304
-49% -$937K ﹤0.01% 2822
2017
Q1 		$1.82M Buy
59,264
+48,370
+444% +$1.51M ﹤0.01% 2179
2016
Q4 		$365K Buy
10,894
+10,096
+1,265% +$289K ﹤0.01% 3664
2016
Q3 		$21K Buy
798
+423
+113% +$9.82K ﹤0.01% 5450
2016
Q2 		$9K Sell
375
-1,869
-83% -$48.9K ﹤0.01% 5573
2016
Q1 		$65K Buy
2,244
+1,862
+487% +$51.8K ﹤0.01% 4624
2015
Q4 		$13K Sell
382
-4,543
-92% -$148K ﹤0.01% 5328
2015
Q3 		$177K Buy
4,925
+4,557
+1,238% +$196K ﹤0.01% 4217
2015
Q2 		$17K Sell
368
-371
-50% -$14.4K ﹤0.01% 5775
2015
Q1 		$22K Sell
739
-93
-11% -$3.62K ﹤0.01% 5775
2014
Q4 		$43K Sell
832
-37,516
-98% -$1.68M ﹤0.01% 5836
2014
Q3 		$1.5M Sell
38,348
-30,540
-44% -$1.22M ﹤0.01% 2943
2014
Q2 		$2.96M Sell
68,888
-11,571
-14% -$441K ﹤0.01% 2236
2014
Q1 		$3.14M Sell
80,459
-72,584
-47% -$2.64M ﹤0.01% 2124
2013
Q4 		$4.13M Sell
153,043
-54,234
-26% -$1.31M ﹤0.01% 1988
2013
Q3 		$4.56M Buy
207,277
+27,708
+15% +$529K 0.01% 1756
2013
Q2 		$3.18M Buy
+179,569
New +$3.5M ﹤0.01% 2036

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Barclays's ENTA Position: Q1 2026 in Review

Barclays reduced its Enanta Pharmaceuticals (ENTA) stake by 67% in Q1 2026, selling an estimated $491K and leaving 18,394 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #3600.

Barclays first reported a position in ENTA in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.37M in Q1 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Barclays held 18,394 shares of Enanta Pharmaceuticals worth $232K as of Q1 2026.
  • Barclays sold 36,595 Enanta Pharmaceuticals shares in Q1 2026, an estimated $491K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3600 holding.
  • Barclays first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Enanta Pharmaceuticals position peaked at $5.37M in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.